Altherity Therapeutics (ATHE) Stock Rockets On Clinical Data

Alterity Therapeutics ATHE Stock News

Alterity Therapeutics Ltd (NASDAQ: ATHE) is flying in the market this morning. The gains seem to be the result of a short squeeze triggered by a data presentation that was announced in after-hours yesterday. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

ATHE Stock Flies After Announcing Positive Data

In the press release, Alterity Therapeutics said that it presented data from ATH434 at the American Academy of Neurology virtual meeting. The treatment is being developed as a potential option for patients with Multiple System Atrophy.

ATHE said that the presentation was based on an abstract surrounding a Phase 1 study of PBT434, a novel small molecule inhibitor of a-synuclein aggregation, in adult and older adult volunteers.

Moreover, Dr. Stamler was interviewed by Neurology today. Importantly, te abstract, presentation and article share findings from the company’s completed Phase 1 clinical trial of ATH434. The trial evaluated safety, tolerability, and pharmacokinetics in health adult and older adult volunteers.

The data from this study was overwhelmingly important, yielding three key points of inflection:

  1. First and foremost, ATH434 crosses the blood brain barrier in humans. This is a very difficult barrier to get therapeutic agents through.
  2. Clinically tested doses achieved concentrations in the brain that were comparable to or exceed those associated with efficacy in animal models of disease.
  3. Finally, the drug proved to be safe and well-tolerated in the Phase 1 study. Moreover, a similar adverse event profile was seen in adults both under and over the age of 65.

In a statement, Dr. David Stamler, told Neurology Today te following about the flagship product under development at ATHE:

Because we’re treating the underlying cause of disease by targeting alpha synuclein, I think we have potential to affect all aspects of disease — the motor symptoms, the blood pressure problems, gait and balance, and even bowel and bladder dysfunction.

This Is Big News

The news released by Alterity Therapeutics late yesterday is massive. We’re talking about a small biotech company worth around $10 million. This small company has figured out how to bring a treatment that’s proven to be effective in animal models through the human blood brain barrier.

Moreover, the company did so in a safe and well-tolerated way. That’s impressive by any stretch of the imagination.

Considering this, ATHE stock is one that should be on your radar.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.